[email protected]

Collaboration combines trading expertise and technology to deliver smarter strategies, education, and tools for traders worldwide LONDON, June 09, 2025 (GLOBE NEWSWIRE) — EBC Financial Group (EBC), a global leader in financial brokerage and asset management, is proud to announce a strategic knowledge partnership with Brokeree Solutions, a cutting-edge technology

NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BigBear.ai Holdings, Inc. (NYSE: BBAI) between March 31, 2022 and March 25, 2025, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. SO

Following its merger with Sharethrough, Equativ has tripled in size over three years, expanding global reach and accelerating growth in North America NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) — Equativ today announces the full unification of Sharethrough into its global brand and operations, forming one of the largest global

HONG KONG SAR – EQS Newswire – 9 June 2025 – As sustainable development continues to gain momentum worldwide, the carbon emissions market presents immense growth potential. Hong Kong-listed Unity Group Holdings International Ltd (Unity) (1539.HK) recently unveiled the world’s first ESG Light certified for carbon credits. Its continued promotion

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ibotta, Inc. (NYSE: IBTA): (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Ibotta’s April 18, 2024 initial

NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial